A Phase 1 interventional study of VERVE-102 in Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, sponsored by Verve Therapeutics, Inc.. Recruiting at 27 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Verve Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 45th largest by planned enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 2 of the 17 other live ones, and was the 65th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Wisconsin, Madison · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 6–17
Brigham and Women's Hospital · Sites in United States
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 34 · Phase 4 4
First in 1985; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 85 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 163 across the 68 interventional studies, 22 across the 8 observational. Of the 57 that completed or were terminated, 32 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Verve Therapeutics, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Verve Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Eli Lilly and Company has 4 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Hyperlipoproteinemia Type II with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05284513Geisinger ClinicCollaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH) | 2027-01 |
| NCT05750667Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia | 2027-02-28 |
| NCT07919353Northwestern UniversityPenn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 | 2027-02-28 |
| NCT06743659Brigham and Women's HospitalComputerized Decision Support for Identification and Management of Familial Hypercholesterolemia | 2027-03-30 |
| NCT06439654Atlantic Health SystemAtlantic Lipid Lowering Treatment Optimization Program | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Intravenous (IV) infusion
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: up to Day 365
Evaluation of maximum observed concentration (Cmax)
Time frame: up to Day 365
Evaluation of time to maximum observed concentration (tmax)
Time frame: up to Day 365
Evaluation of terminal elimination half-life (t1/2)
Time frame: up to Day 365
Percent and absolute change from baseline in plasma PCSK9 concentration
Time frame: up to Day 365
Percent and absolute change from baseline in LDL-C
Time frame: up to Day 365
Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →